DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/5682
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorEtienne, Ruth-valine-
dc.date.available2024-05-07-
dc.date.available2024-05-08T17:23:26Z-
dc.date.issued2023-12-01-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/5682-
dc.description.abstractAcute chest syndrome (ACS) is the leading cause of morbidity and mortality in patients with sickle cell disease in any age group. Acute chest syndrome is responsible for about 25% of deaths and about 75% of them occur in the age group up to 29 years old, especially in the first decade of life. The etiology of ACS is multifactorial, with both infectious and non-infectious causes being implicated. In infectious causes, we find bacteria, atypical microorganisms, and viruses; noninfectious causes include fat embolism and pulmonary infarction. However, in a large number of cases it is not possible to define the etiology of ACS. Its pathophysiology comprises pneumonia, infarcts, atelectasis, and intrapulmonary falcization. In the lungs, ACS includes complex lung injury and potentially devastating sequelae. Aims: To analyze the prevalence and incidence of ACS in the REDS-III DF cohort and to verify the association between sociodemographic variables, as well as clinical and biological variables, according to the presence or absence of ACS, Methodology: Cross-sectional and descriptive study conducted using data related to Acute Chest Syndrome collected in the multicenter REDS III project. The REDS-III Brazil DF cohort study was designed to assess the pathogenesis of DF and the impact of transfusion on disease outcomes, which is a collaboration between American researchers at the Vitalant Research Institute in San Francisco, California, and researchers at several Hemocenters in Brazil: Hemope, Hemorio, Hemominas, and Instituto da Criança at the Hospital das Clínicas of the Faculty of Medicine of the University of São Paulo. The cohort included patients aged 0-77 years, through interview with project participants, review of participants' medical records and collection of biological material. The project has already been approved by the Research Ethics Committee of the Faculty of Medicine of the University of São Paulo (FMUSP), as well as the Research Ethics Committee of Hemoam. Results: A total of 2793 patients with a diagnosis of sickle cell disease of both sexes took part in this study. 1833 had experienced ACS at least once in their lives, giving a prevalence of 65.6%. The general incidence was 8,3 %, but in children it was 9,5 % . The overall mortality rate was 13.4%, and was higher among adults, 11.2%. The majority of ACS cases occurred in the 11-20 age group (72.4%) and the majority of participants had attended elementary school: 67.9%. The SCD subtypes most associated with the development of STA were HbSS and HbSß0. The history of asthma in STA patients was 88.3% and patients without STA accounted for 11.7%. The majority of patients with ACS had a previous history of VOE: 94.4%. Hemoglobin level was lower and platelet, leukocyte and reticulocyte counts were higher in patients with ACS. Conclusion: The results obtained show the high prevalence of STA in patients with sickle cell disease. These data, especially the mortality rate found, explain why it is considered one of the most frequent and serious complications of the diseasept_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectSindrome torácica agudapt_BR
dc.subjectDoença falciformept_BR
dc.subjectacute chest syndromept_BR
dc.subjectsickle cell diseasept_BR
dc.titleSindrome torácica aguda em pacientes com doença falciforme: caracterização demográfica e identificação de fatores predisponentespt_BR
dc.title.alternativeAcute chest syndrome in patients with sickle cell disease: demographic characterization and identification of predisposing factorspt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2024-05-08T17:23:26Z-
dc.contributor.advisor-co1Frantz, Sonia Rejane de Senna-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/2654817058533157pt_BR
dc.contributor.advisor1Fraiji, Nelson Abrahim-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/5204063085335824pt_BR
dc.contributor.referee1Fraiji, Nelson Abrahim-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/5204063085335824pt_BR
dc.contributor.referee2Passos, Leny Nascimento da Motta-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/8194622149198642pt_BR
dc.contributor.referee3Paula, Erich Vinicius de-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/0983518713985469pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/2604287727752816pt_BR
dc.description.resumoA Síndrome torácica aguda (STA) constitui a principal causa de morbidade e mortalidade em pacientes com Doença Falciforme (DF), em qualquer faixa etária. A STA é responsável por cerca de 25% dos óbitos e, cerca de 75% deles ocorre na faixa etária de até 29 anos, sobretudo na primeira década de vida. A etiologia da STA é multifatorial, sendo implicadas causas infecciosas e não infecciosas. Nas causas infecciosas, encontramos bactérias, microrganismos atípicos e vírus; as causas não infecciosas incluem a embolia gordurosa e o infarto pulmonar. Entretanto, em elevado número de casos não é possível definir a etiologia da STA. Sua fisiopatologia compreende pneumonia, infartos, atelectasias e falcização intrapulmonar. Nos pulmões, a STA provoca lesão pulmonar complexa e sequelas potencialmente devastadoras. Objetivos: Analisar a prevalência e incidência de STA na coorte REDS-III DF e verificar a associação entre variáveis sociodemográficas, clínicas e biológicas, segundo a presença ou ausência de STA. Metodologia: Estudo transversal e descritivo realizado através de dados relacionados com Síndrome Torácica, coletados no projeto multicêntrico REDS III. O Projeto REDS III é uma colaboração entre pesquisadores americanos do Vitalant Research Institute, em São Francisco, Califórnia e pesquisadores em vários Hemocentros do Brasil: Hemope, Hemorio, Hemominas e Instituto da criança no Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. O estudo de coorte REDS-III Brasil DF foi desenhado para avaliar a patogênese da DF e o impacto da transfusão nos resultados da doença. Nosso estudo foi realizado em pacientes de 0-77 anos, através de entrevista com os participantes do projeto, revisão dos prontuários médicos dos participantes e coleta de material biológico. O projeto foi aprovado pelo Comitê de Ética em Pesquisa da Faculdade de Medicina da Universidade de São Paulo (FMUSP), portanto não foi necessária sua aprovação pelo Comitê de Ética do Hemoam. Resultados: Participaram deste estudo 2793 pacientes com diagnóstico de doença falciforme de ambos os sexos. 1833 tiveram STA pelo menos 1 vez na vida determinando uma prevalência de 65.6%. A taxa de incidência global foi de 8.3% e de 9,5 % em crianças. A taxa de mortalidade global foi 13.4%, tendo sido maior entre os adultos, 11.2 %. A maioria dos casos de STA ocorreu na faixa etária de 11-20 anos (72.4%) e 67.9 % dos participantes cursaram o ensino fundamental. Os subtipos de DF mais associados ao desenvolvimento de STA, foram HbSS e HbSß0. Antecedentes de asma em pacientes com ou sem STA, foi registrado em 88.3% e 11.7 % respectivamente. Na maioria dos pacientes com STA (94.4%), foi registrado história pregressa de STA. O nível de hemoglobina foi mais baixo e as contagens de plaquetas, leucócitos e reticulócitos foram mais elevados em pacientes com STA. Conclusão: Os resultados obtidos mostram a elevada prevalência de STA em pacientes com Doença Falciforme. Esses dados, assim como a taxa de mortalidade encontrada, explicam porque a STA é considerada uma das complicações mais frequentes e mais grave da doençapt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references48 12- Brunetta DM, Clé DV, Haes TM, Roriz-Filho JS, Moriguti JC. Manejo das complicações agudas da doença falciforme. InCID: Revista de Ciência da Informação e Documentação. 2010 Sep 30;43(3):231-7. 13- Tanabe P, Spratling R, Smith D, Grissom P, Hulihan M. CE: Understanding the Complications of Sickle Cell Disease. Am J Nurs. 2019 Jun;119(6):26-35. doi: 10.1097/01.NAJ.0000559779.40570.2c. PMID: 31135428; PMCID: PMC6674980. 14- Monteiro AC, Dorigatti DH, Rodrigues AG, da Silva JB. Sickle cell anemia, a genetic disorder characterized by the change in shape of red blood cells. Saúde em Foco, Edição nº. 2015; 7:107- 118. 15- Usmani A, Machado RF. Vascular complications of sickle cell disease. Clinical Hemorheology and Microcirculation 2018;68: 205–221. 16- da Silva AH, Bellato R, de Araújo L F S. The everyday life of families who experience the chronic condition of sickle-cell anemia. Rev. Eletr. Enf. abr/jun 2013; 15: 437- 446.doi.org/10.5216/ree. v15i2.17687, 17- Pinto VM, Balocco M, Quintino S. et al. Sickle cell disease: a review for the internist. Intern Emerg Med 2019 14, 1051–1064 . doi.org/10.1007/s11739-019-02160-x 18- Zanatta T, Manfredini V. Comparação entre métodos laboratoriais de diagnóstico de Doenças Falciformes. Newslab, 2009; 94:180-194. 19- Belisário AR, Blatyta PF, Vivanco D, Oliveira CDL. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infect Dis. 2020 Aug 27;20(1):638. doi: 10.1186/s12879-020-05366-z. PMID: 32854639; PMCID: PMC7457248. 20- Conran N, De Paula EV. Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance. Haematologica. 2020 Oct 1;105(10):2380-2390. doi: 10.3324/haematol.2019.239343. PMID: 33054078; PMCID: PMC7556678. 21- Mehari A, Klings ES. Chronic Pulmonary Complications of Sickle Cell Disease. Chest. 2016 May;149(5):1313-24. doi: 10.1016/j.chest.2015.11.016. Epub 2016 Jan 13. PMID: 26836905; PMCID: PMC6026273. 22- Carneiro-Proietti ABF, Kelly S, Miranda Teixeira C. Clinical and genetic ancestry profile of a large multi-centre sickle cell disease cohort in Brazil. Br J Haematol. 2018 Sep;182(6):895-908. doi: 10.1111/bjh.15462. Epub 2018 Jul 19. PMID: 30027669; PMCID: PMC8019534. 49 23- Hostyn SV, Johnston C, Braga JA, Carvalho WB, Nogueira SC. Fisioterapia respiratória em crianças com doença falciforme e síndrome torácica aguda. Revista Paulista de Pediatria. 2011;29:663-8. 24- Arduini, GA, Rodrigues LP, Trovo de Marqui AB. Mortality by sickle cell disease in Brazil. Rev Bras Hematol Hemoter, 2017. 39(1): 52-56. 25- Felix, AA, Souza HM, Ribeiro FB. Epidemiological and social aspects of sickle cell disease: Rev. Bras. Hemato e Hemo 2010; 32: 203-208. 26- Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Prim. 2018; 4: 1–22. 27- Houwing ME, De Pagter PJ, Van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, Schols EM, Philipsen JN, Tamminga RY, van Draat KF, Nur E. Sickle cell disease: clinical presentation and management of a global health challenge. Blood reviews. 2019 Sep 1; 37:100580. 28- Jain D, Atmapoojya P, Colah R, Lodha P. Sickle Cell Disease and Pregnancy. Mediterr J Hematol Infect Dis. 2019 Jul 1;11(1):e2019040. doi: 10.4084/MJHID.2019.040. PMID: 31308916; PMCID: PMC6613624 29- de Almeida R A; Remédio A L Z B. Sickle Cell Disease and laboratory approach: a brief literature review RBAC ; 2017; 49: 131-134. 30- Sudário LC, Kroger FL, de Paula NC, dos Santos OF, Cintra RB, Rodrigues DD. Doença Falciforme e aspectos previdenciários. Brazilian Journal of Health Review. 2020 Dec 10;3(6):18259-70. 31- Alvarez O, Wietstruck, M.A. Sickle Cell Disease. In: Bertrand, P; Sanchez, I. (eds) Pediatric Respiratory Disease. Springer, Cham. Feb2020:529-541. doi.org/10.1007/978- 3-030-26961-6_52. 32- Asnani M R, Knight Madden J, Reid M, Greene L G, Lyew-Ayee, P. Socio-environmental exposures and health outcome samong persons with sickle cell disease. PLoS ONE one,12,2017, e0175260: 1-12. 33- Driscoll M C. Sickle Cell Disease. Pediatrics in Review. July 2007; 28: 259-268. 34- Osunkwo I, Andemariam B, Minniti CP, Inusa BP, El Rassi F, Francis‐Gibson B, Nero A, Trimnell C, Abboud MR, Arlet JB, Colombatti R. Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). American Journal of Hematology. 2021 Apr;96(4):404-17. 50 35- Zago, M A; Silva Pinto A C; The phisiopatology of sickle cell disease: From the genetic mutation to multiorgan disfunction. Rev. Bras de Hemato e Hemo. 2007; 29: 207-214. 36- Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Frontiers in physiology. 2020 May 20;11: 435: 1-15. 37- Jang T, Poplawska M, Cimpeanu E, Mo G, Dutta D, Lim SH. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. Journal of Translational Medicine. 2021 Dec;19(1):1-1. 38- Darbari D S, Sheehan VA, Ballas SK. The vaso‐occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. European journal of haematology. 2020 Sep;105(3):237-46. 39- de Souza, J M; Rosa P E L; Souza R L; de Castro G F P. FISIOPATOLOGIA DA ANEMIA FALCIFORME Rev. Transf. 2016; Itaperuna 8:162-177. 40- Martins P R J, Moraes-Souza H, Braga S T. Morbidity-mortality in sickle cell disease. Revista Brasileira de Hematologia e Hemoterapia 2010; 32:378-383. 41- Manfredini V, Castro S, Wagner S, Benfato M S. A Fisiopatologia da anemia falciforme. Infarma, 2007, v.19, nº 1/2, :3-6. 42- Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017 Apr 20;376(16):1561-1573. doi: 10.1056/NEJMra1510865. PMID: 28423290. 43- Heeney M M; Ware Russell E. Hydroxyurea for Children with Sickle Cell Disease. Ped. Clinic Of North America, 2008; 55: 483–501. 44- Odièvre MH, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell disease. The Indian journal of medical research. 2011 Oct;134(4): 532-537. 45- Loureiro MM, Rozenfeld S. Epidemiology of sickle cell disease hospital admissions in Brazil. Revista de Saúde Pública. 2005; 6, 39: 943-949. 46- Aragão de Jesus J, Cortez de Araújo P I. Doença Falciforme, Condutas básicas para tratamento. Serie B, textos básicos da Saude. Brasilia,2012. 47- Chamba C, Iddy H, Tebuka E, Tluway F, Osati E, Budodi N et al . "Limited Exchange Transfusion Can Be Very Beneficial in Sickle Cell Anemia with Acute Chest Syndrome: A Case Report from Tanzania", Case Reports in Hematology.vol. 2018, Article ID 5253625, 3 pages, 2018.doi.org/10.1155/2018/5253625 48- Badaki-Makun O, Casella JF, Tackett S, Tao X, Chamberlain JM. Association of antibiotic choice with hospital length of stay and risk factors for readmission in patients with sickle cell disease and acute chest syndrome: an observational cohort study. Annals of emergency medicine. 2020 Sep 1;76(3): 37-45. 51 49- Saleh M, Asemota J. Severe Acute Chest Syndrome in a Sickle Cell Patient That Required Repeated Exchange Transfusion. Cureus. February 01, 2021 13(2): e13066. DOI 10.7759/cureus.13066 50- Novelli EM, Gladwin MT. Crises in sickle cell disease. Chest. 2016 Apr 1;149(4):1082- 93. 51- Assad Z, Michel M, Valtuille Z, Lazzati A, Boizeau P, Madhi F, Gaschignard J, Pham LL, Caseris M, Cohen R, Kaguelidou F. Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine in France. JAMA Network Open. 2022 Aug 1;5(8):e2225141; 1-14. 52- Gordon A. Laurie. Acute Chest Syndrome in Sickle Cell Disease. Internal medicine journal. 2010, vol 40 (5) p. 372-376. 53- Leonard A, Godiwala N, Herrera N, McCarter R, Sharron M, Meier ER. Early initiation of inhaled corticosteroids does not decrease acute chest syndrome morbidity in pediatric patients with sickle cell disease. Blood Cells, Molecules, and Diseases. 2018 Jul 1;71:55- 62. 54- Vinchisky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342: 1855-1864. 55- Nourani AR, Fazlur Rahman AK, Pernell B, Maddox MH, Hilliard L, Lebensburger J, Alishlash AS. Nocturnal hypoxemia measured by polysomnogram is associated with acute chest syndrome in pediatric sickle cell disease. Journal of Clinical Sleep Medicine. 2021 Feb 1;17(2):219-26. 56- Annadatha A, Talwar D, Acharya S, Kumar S, Lahane V. Acute Chest Syndrome, Avascular Necrosis of Femur, and Pulmonary Embolism All at Once: An Unexpected Encounter in the First-Ever Admission of a Sickle Cell Patient. Cureus. 2021 Sep 1;13(9): 2-7. 57- Cheminet G, A. Mekontso-Dessap, J. Pouchot, J.-B. Arlet, Syndrome thoracique aigu chez les patients drépanocytaires adultes, La Revue de Médecine Interne, 2023 ;43, Issue (8)470-478,ISSN02488663, doi.org/10.1016/j.revmed.2022.04.019.doi.org/10.1016/j.bjhh.2016.09.008 58- Allareddy V, Roy A, Lee MK, Nalliah RP, Rampa S, Allareddy V, Rotta AT. Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality. PLoS One. 2014 Apr 16;9(4):e94387. 52 59- Koehl JL, Koyfman A, Hayes BD, Long B. High risk and low prevalence diseases: Acute chest syndrome in sickle cell disease. The American Journal of Emergency Medicine. 2022 Aug 1;58:235-44. 60- Takahashi T, Okubo Y, Pereda MA, Handa A, Miller S. Factors associated with mechanical ventilation use in children with sickle cell disease and acute chest syndrome. Pediatric Critical Care Medicine. 2018 Sep 1;19(9):801-9. 61- Klings ES, Steinberg MH. Acute chest syndrome of sickle cell disease: Genetics, risk factors, prognosis, and management. Expert Review of Hematology. 2022 Feb 1;15(2):117-25. 62- Seaman CD, Novelli E, De Castro L, Ragni MV. Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome. Pilot and Feasibility Studies. 2020 Dec;6(1):1- 8. 63- Allen B, Molokie R, Royston TJ. Early Detection of Acute Chest Syndrome Through Electronic Recording and Analysis of Auscultatory Percussion. IEEE Journal of Translational Engineering in Health and Medicine. 2020 Sep 30;8:1-8. 64- Ogunlesi F, Heeney MM, Koumbourlis AC. Systemic corticosteroids in acute chest syndrome: friend or foe?. Paediatric respiratory reviews. 2014 Mar 1;15(1):24-7. 65- Miller ST. How I treat acute chest syndrome in children with sickle cell disease. Blood, The Journal of the American Society of Hematology. 2011 May 19;117(20):5297-305. 66- Sysol JR, Machado R. Sickle cell disease and acute chest syndrome: epidemiology, diagnosis, management, outcomes. Hematologic Abnormalities and Acute Lung Syndromes. 2017:67-87. 67- Howard J, Hart N, Roberts‐Harewood M, Cummins M, Awogbade M, Davis B, BCSH Committee. Guideline on the management of acute chest syndrome in sickle cell disease. British journal of haematology. 2015 May;169(4):492-505. 68- Dolatkhah R, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews. 2020(1). Art. No.: CD007843. DOI: 10.1002/14651858.CD007843.pub4. 69- Patterson GD, Mashegu H, Rutherford J, Seals S, Josey D, Karlson C, McNaull M, May W, Carroll C, Barr FE, Majumdar S. Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: Clinical Features and Risk Factors. J Pediatr Hematol Oncol. 2018 Jan;40(1):51-55. doi: 10.1097/MPH.0000000000001012. PMID: 29200151; PMCID: PMC10182404. 53 70- Abbas HA, Kahale M, Hosn MA, Inati A. A review of acute chest syndrome in pediatric sickle cell disease. Pediatric annals. 2013 Mar 1;42(3):115-20. 71- da Costa Pinto FP, da Silva HC, Pozzobon CR. Síndrome torácica aguda grave com evolução para síndrome do desconforto respiratório agudo. Pulmão RJ. 2006;15(2):117- 20. 72- Gualandro SF, Fonseca GH, Gualandro DM. Complicações cardiopulmonares das doenças falciformes. Revista Brasileira de Hematologia e Hemoterapia. 2007;29:291-8. 73- Omar M, Jabir AR, Khan I, Novelli EM, Xu JZ. Diagnostic Test Accuracy of Lung Ultrasound for Acute Chest Syndrome in Sickle Cell Disease: A Systematic Review and Meta-analysis. Chest. 2022 Dec 9. 74- Madhi F, Kamdem A, Jung C, Carlier-Gonod A, Biscardi S, Busca J, Arnaud C, Hau I, Narbey D, Epaud R, Pondarre C. Identification of clinical and laboratory parameters associated with the development of acute chest syndrome during Vaso-occlusive episodes in children with sickle cell disease: A preliminary step before assessing specific and early treatment strategies. Journal of clinical Medicine. 2019 Nov 1;8(11):1839. 75- Dastgiri S, Dolakath R. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Revoews 2016, Issue 8. CD007843, DOI: 10.1002/14651858.CD007843.pub3 76- Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annual review of pathology: mechanisms of disease. 2019 Jan 24;14:263-92. 77- BOK YOO HH, Pelegrino NR, CARLOS AL, GODOY ID, Queluz TT. Acute chest syndrome as the first manifestation of sickle cell disease in a middle aged adult. Jornal de Pneumologia. 2002;28:237-40. 78- Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. New England journal of medicine. 2008 Nov 20;359(21):2254-65. 79- Alhashimi D, Fedorowicz Z, Alhashimi F, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews. 2010(1). Art. No: CD00784, 2010. 80- Lopinto J, Elabbadi A, Gibelin A, Voiriot G, Fartoukh M. Infectious aetiologies of severe acute chest syndrome in sickle-cell adult patients, combining conventional microbiological tests and respiratory multiplex PCR. Scientific Reports. 2021 Mar 1;11(1):4837.doi: 10.1038/s41598-021-84163-3. 81- Habibi A, Arlet JB, Stankovic K, Gellen-Dautremer J, Ribeil JA, Bartolucci P, Lionnet F. Recommandations françaises de prise en charge de la drépanocytose de l'adulte: 54 actualisation 2015. La Revue de Médecine Interne. 2015 May 11;36(5):5S3- 84..doi.org/10.1016/S0248-8663(15)60002-9. 82- Meier E, Rampersad A. Pediatric sickle cell disease: past successes and future challenges. Pediatric research. Jan 2016; 81:249-258. 83- Bundy DG, Richardson TE, Hall M, Raphael JL, Brousseau DC, Arnold SD, Kalpatthi RV, Ellison AM, Oyeku SO, Shah SS. Association of guideline-adherent antibiotic treatment with readmission of children with sickle cell disease hospitalized with acute chest syndrome. JAMA pediatrics. 2017 Nov 1;171(11):1090-9. 84- Munaretto V, Corti P, Bertoni E, Tripodi SI, Guerzoni ME, Cesaro S, Arcioni F, Piccolo C, Mina T, Zecca M, Cuzzubbo D. Acute chest syndrome in children with sickle cell disease: Data from a national AIEOP cohort identify priority areas of intervention in a hub‐and‐spoke system. British Journal of Haematology. 2023 Sep 6:1–6. DOI: 10.1111/bjh.19084 85- Lopes de Castro Lobo, C., Pinto, J.F.C., Nascimento, E.M., Moura, P.G., Cardoso, G.P. and Hankins, J.S. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013, 161: 852-860. 86- Torres LD, Silva DG, Belini Junior E, Almeida EA, Lobo CL, Cançado RD, Ruiz MA, Bonini-Domingos CR. The influence of hydroxyurea on oxidative stress in sickle cell anemia. Revista Brasileira de Hematologia e Hemoterapia. 2012; 34:421-5. 87- Beck CE, Trottier ED, Kirby-Allen M, Pastore Y. Acute complications in children with sickle cell disease: Prevention and management. Paediatrics & Child Health. 2022 Mar 1;27(1):50-5. doi.org/10.1093/pch/pxab096 88- Elendu C, Amaechi DC, Alakwe-Ojimba CE, Elendu TC, Elendu RC, Ayabazu CP, Aina TO, Aborisade O, Adenikinju JS. Understanding Sickle cell disease: Causes, symptoms, and treatment options. Medicine. 2023 Sep 22;102(38):e35237. 89- Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008 Dec 1;122(6):1332-42. 90- Vadehra D, Davino T, Datta D. Treating a Patient with Your Hands Tied: Acute Chest Syndrome in a Jehovah’s Witness. Cureus. 2020 Apr 21;12(4). p. 1-5 91- Field JJ, Willen S, DeBaun MR. Acute chest syndrome (ACS) in sickle cell disease (adults and children). UpToDate, Waltham, MA. Accessed on July. 2022 Nov 10;19. 55 92- Linder GE, Chou ST. Red cell transfusion and alloimmunization in sickle cell disease. Haematologica. 2021 Jul 1;106(7): 1805-1815.doi: 10.3324/haematol.2020.270546. PMID: 33792218; PMCID: PMC8252926. 93- DeBaun MR, Strunk RC. The intersection between asthma and acute chest syndrome in children with sickle-cell annemia. The Lancet. 2016 Jun 18;387(10037): 2545- 53.doi.org/10.1016/S0140-6736(16)00145-8. 94- van Tuijn CF, Gaartman AE, Nur E, Rijneveld AW, Biemond BJ. Incentive spirometry to prevent acute chest syndrome in adults with sickle cell disease; a randomized controlled trial. American Journal of Hematology. 2020 Jul;95(7): E160. 95- Alkindi S, Al-Busaidi I, Al-Salami B, Raniga S, Pathare A, Ballas SK. Predictors of impending acute chest syndrome in patients with sickle cell anaemia. Scientific Reports. 2020 Feb 12;10(1); 2470; 128-33. 96- Dubois G, Virot E, Marie M, Poutrel S, Cannas G, Hot A. Impact of COVID‐19 on incidence, clinical presentation, and prognosis of acute chest syndrome in patients with sickle cell disease. eJHaem. 2023:1-7 97- Daswani DD, Shah VP, Avner JR, Manwani DG, Kurian J, Rabiner JE. Accuracy of Point-of-care Lung Ultrasonography for Diagnosis of Acute Chest Syndrome in Pediatric Patients with Sickle Cell Disease and Fever. Acad Emerg Med. 2016 Aug;23(8):932-40. doi: 10.1111/acem.13002. 98- Boyd, J.H.; Macklin, E.; Strunk, R.C.; DeBaun, M.R. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006, 108, 2923– 2927. 99- Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005 Mar;60(3):206-10. doi: 10.1136/thx.2004.029165. 100- Helvaci MR, Acipayam C, Aydogan A, Akkucuk S, Oruc C, Gokce C. Acute chest syndrome in severity of sickle cell diseases. Int J Clin Exp Med. 2014 Dec 15;7(12):5790- 5. 101- Knight-Madden JM, Barton-Gooden A, Weaver SR, Reid M, Greenough A. Mortality, asthma, smoking and acute chest syndrome in young adults with sickle cell disease. Lung. 2013 Feb;191:95-100.doi.org/10.1007/s00408-012-9435-3 102- Jadhav U, Babu R, Ghewade B, Lanjewar A, Gandhasiri D. Acute chest syndrome, a distinctive manifestation in sickle cell disease–A case study. Journal of Datta Meghept_BR
dc.subject.cnpqHematologiapt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.